RIGL’s Earnings Plummet. Why the Stock Is Cheap

Forward-Looking Analysis

Rigel Pharmaceuticals (RIGL) faces significant headwinds heading into its August 4, 2026, second-quarter earnings report. Analyst consensus forecasts a sharp decline in profitability, with earnings per share (EPS) projected at just $0.09, a substantial drop from the $3.28 EPS recorded in the same quarter last year. This forecast reflects a broader trend of contracting top-line performance, as revenue is expected to fall to $55.27 million, down from the $58.82 million reported in the first quarter of 2026 and significantly below the $62.40 million estimate from the prior quarter.

The valuation metrics suggest the market has already priced in these challenges. With a Price-to-Earnings (P/E) ratio of 1.97, RIGL trades at a discount compared to the market average of 40.27 and the healthcare sector average of 282.64. This low multiple, combined with a Price-to-Book (P/B) ratio of 1.71, indicates the stock is reasonably valued relative to its assets but highlights the compressed earnings potential. Analyst coverage remains limited, with four recent reports supporting a "Hold" consensus and an average price target of $54.50, implying a 48.1% upside from the current price of $36.81. However, the modest 7.41% projected earnings growth over the next year underscores cautious expectations. The divergence between the low current EPS forecast and the higher long-term projections suggests investors are awaiting clearer signs of revenue stabilization or new catalysts, such as the expansion of fostamatinib into IgA nephropathy, to drive future growth. Currently, the data points to a period of consolidation and margin pressure rather than aggressive expansion.

Rigel Pharmaceuticals delivered a mixed but generally disappointing first quarter of 2026. The company reported revenue of $58.82 million, missing the $62.40 million consensus estimate. Net income stood at $8.65 million, a stark decrease from the $268.06 million reported in the previous quarter, reflecting a 96.77% sequential decline. Earnings per share came in at $0.44, significantly below the $0.80 forecast, resulting in a -44.67% earnings surprise. While gross profit remained robust at $54.21 million, the overall financial picture was marred by the revenue miss and the substantial drop in net income, signaling ongoing challenges in maintaining the high profitability levels seen in late 2025.

Additional News

Rigel Pharmaceuticals has recently undertaken key organizational changes to strengthen its scientific leadership. On July 1, 2026, the company appointed Board Member Alison L. Hannah, M.D., as its new Chief Medical Officer. This leadership addition coincides with the company's ongoing efforts to advance its clinical pipeline, particularly the exploration of its lead drug, fostamatinib, in new indications like IgA nephropathy. Additionally, on July 7, 2026, Rigel announced inducement grants under NASDAQ Listing Rule 5635(c)(4), likely aimed at retaining talent amidst its clinical-stage operations. These moves indicate a strategic focus on bolstering executive expertise to drive the translation of its small molecule therapeutics from bench to bedside. The company continues to leverage its proprietary chemistry platform and signal transduction expertise to address unmet medical needs in immune and hematologic diseases, maintaining its commitment to regulatory engagement and academic collaboration.

Summary & Outlook

Rigel Pharmaceuticals exhibits a cautious financial outlook for Q2 2026. Revenue is projected to decline to $55.27 million, with EPS expected to plummet to $0.09 from $3.28 year-over-year. This contraction reflects recent misses in Q1 2026, where revenue fell short of estimates and net income dropped sharply. While the company maintains a low P/E ratio, indicating potential undervaluation, the lack of dividend payments and shrinking earnings momentum present risks. The primary growth catalyst lies in the clinical expansion of fostamatinib. Given the significant earnings downgrade and revenue decline, the near-term prospect is neutral to bearish. Investors should monitor upcoming clinical data and commercial execution for any signs of stabilization before considering a bullish stance.